US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1

Is a

Patent

Patent attributes

Patent Applicant

Bristol-Myers Squibb Company

Current Assignee

Bristol-Myers Squibb Company

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

119524210

Patent Inventor Names

Ralf Hosse0

Wolfgang Schaefer0

Klaus Strein0

Christian Klein0

Minh Diem Vu0

Sabine Jung-Imhof0

Ekkehard Moessner0

Tanja Fauti0

...

Date of Patent

April 9, 2024

Patent Application Number

155172960

Date Filed

October 8, 2015

Patent Citations

‌

US Patent 8592562 Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects

‌

US Patent 9228023 Anti-ROR1 antibodies and methods of use for treatment of cancer

‌

US Patent 9963513 Method for the selection of antibodies against BCMA

‌

US Patent 10077315 Bispecific antibodies against CD3 and BCMA

‌

US Patent 10233237 Heterodimeric immunoglobulins

‌

US Patent 10253104 Bispecific antibodies against CD3ϵ and BCMA

‌

US Patent 10683369 Monoclonal antibodies against BCMA

‌

US Patent 10968276 Optimized anti-CD3 variable regions

...

Patent Primary Examiner

‌

Stephen L. Rawlings

Patent abstract

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1